In the case of EGFR, immunohistochemical studies showed that 12.19% of patients with pancreatic cancer did not show tissue expression of the tumor for EGFR, while in the case of patients with low/medium expression, it was 34.15%. This evidence concerns the gene EGFR and neoplasm.